MRNA 2X Long ETF

Everybody now watching the $Moderna(MRNA.US)

$Merck(MRK.US)

Don watch AI anymore 😂💊💊

Wow, the surge in Moderna’s price is impressive but it’s probably too late to chase. I will resist the temptation of FOMO. Better to miss out than be trapped bag holding.

The 3 local banks have stabilised a little following the previous few days of down sessions for the whole SG market. This is good for the longer scheme of things as historical statistics show that steep rise s n share prices are more likely than not followed by steep drawbacks afterwards. Let them consolidate, though I know many are still buying either for long term or just trying to jump on bandwagon.

$Eli Lilly(LLY.US)

Merck and moderna are good examples of what it means to get in and be patient. Lily is pumping so much money into research and with AI we might find a cure for diabetes. Get in and be patient. Trials take time for approvals. Diversify from tech!

$Moderna(MRNA.US)

Moderna’s 177% surge highlights the power of major healthcare catalysts, though chasing such sharp moves comes with significant volatility risk. US markets remained relatively stable while AI chip and semiconductor stocks stayed selective amid new deals and rising competition. Jobless claims remain an important Fed signal,as a cooling labor market could strengthen the case for rate cuts, while resilient employment may keep yields elevated. Overall markets are balancing AI and healthcare growth opportunities against high valuations and broader macroeconomic risks.

Moderna shares jumping by 177% after its melanoma vaccine, developed by Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial, just shows the exact risk-benefit schema of investing in pharmaceutical companies. A brilliant breakthrough like the abovementioned could set new historic records and push the stock higher than ever, but also most of the time experiments fail and trials don't pass the tests. Congratulations to Moderna holders, but I for one will definitely not FOMO or regret not having a position in the stock because I know my own investing strategy.

I’d be very cautious chasing Moderna after a 177% one-day surge. The Phase 3 result is genuinely significant and could reshape the long-term cancer treatment market, but the stock has already priced in a huge amount of optimism. I’d rather wait for the initial excitement to cool and see how the commercial opportunity develops.

What interests me more is the semiconductor split. I’m still constructive on memory names like MU and SNDK given the tight AI-memory supply, but the weakness in WDC, COHR and NBIS shows how quickly funding, valuation and profit-taking can change sentiment. For me, this is a market where fundamentals matter more than simply chasing the biggest one-day winner.

Yay! US has shown their intent and are telling the bond market not to have ideas as they will defend yields no matter what FUD the narratives are.

The +177% rally in $Moderna is a massive clinical milestone for mRNA tech, but chasing a parabolic move at this level carries significant downside risk.

While long-term growth for oncology mRNA therapies with $Merck looks promising, short-term profit taking and insider selling are real risks after such a huge leap. I’d rather sit this initial surge out and wait for a healthy pullback to build a position safely.

didnt manage to scalp and trade the Moderna stock. what a waste. but well, it is still a good news for holders and the world

Modena stock not certain if its a pump and dump after the news and upside yesterday but generally if you want to invest in healthcare or even in the bio field can consider etf with Modena in it for long term investment. Do not all in money, DCA slowly and see if its temporary demand and expectations issues.

It was just a few days ago I mentioned the likelihood of yield curve control and that the US will not sacrifice the stock market at the expense of the bond vigilantes. There were the usual skeptics and rightly so because the textbooks teach you certain things. But the real world is not textbook and the more experienced ones out there will know what I mean. That’s why I keep stating that I am sharing my own opinions and not asking people to agree. 😎

Markets are increasingly differentiating between strong AI-related demand and funding or margin concerns. Semiconductor moves highlight shifting competitive dynamics in custom AI chips, while the Fed minutes reinforce uncertainty over the inflation path and potential policy tightening. Consumer results remain mixed, with resilient sales offset by cautious guidance. Nebius’ financing underscores the capital intensity of AI infrastructure and investors’ sensitivity to dilution and funding requirements.

MRNA just went vertical. A 177% one-day jump after its personalised cancer vaccine hit a major Phase 3 milestone is huge. The science is getting interesting, but the valuation has run ahead of fundamentals. I’d Hold, not chase. Let the dust settle before adding.

Wow what exciting news from Moderna ! So happy to hear that science is evolving and Moderna is one of the key spearheads in the industry.

Modena, a famous COVID-19 vaccine maker. Yesterday it's share price jumping up to 170%. anyone here able to make profit after yesterday jump of it's share price?

$Moderna(MRNA.US) +177% is validation that mRNA isn’t just for COVID. First Phase 3 cancer win with $Merck(MRK.US) opens a massive new market. And SK Hynix buying back means memory demand is real - $Sandisk(SNDK.US) and $Micron Tech(MU.US) catching that bid makes sense.

During Fed chair Warsh's press conference after the Jul meeting, he repeated pointed to the elevated bond yields as a market driven tightening and hence Fed could fold their hands for the moment. However, Treasury secretary Bessent just served the tennis ball back when he announced yesterday that bond buy backs would be minimally doubled. Is Mr Bessent triggering the "test the new Fed chair" rite of passage?